SRAX has entered into a definitive merger agreement with DNA Holdings Venture Inc.
Upon the closing of the merger, DNA shareholders will become the majority owners of SRAX's outstanding common stock.
DNA is currently a long-term investor in SRAX and owns approximately 35% of the company.
The merger is subject to certain contingencies outlined in the definitive agreement to be filed with the SEC.
Upon the completion of the merger, the public company plans to change its name to DNA Holdings Venture Inc and to request to change its ticker symbol.
SEQUIRE intends to work with their clients to help them explore methods by which they can capitalize from decentralized finance and the tokenization opportunities.
The boards of directors of SRAX and DNA have unanimously approved the proposed Transaction.
The proposed Transaction is subject to the approval of both SRAX and DNA stockholders and satisfaction or waiver of the conditions stated in the Agreement.
The parties believe that SRAX’s ability to reach a database of millions of investors is uniquely positioned to educate and inform on the benefits of investing in the decentralized ecosystem.
The parties also believe that SRAX is uniquely positioned to enhance a platform to provide investor insights for Web3 projects.